Effect of temozolomide on the viability of musculoskeletal sarcoma cells

Kusabe,Yuta; Kawashima,Hiroyuki; Ogose,Akira; Sasaki,Taro; Ariizumi,Takashi; Hotta,Tetsuo; Endo,Naoto

doi:10.3892/ol.2015.3506

Effect of temozolomide on the viability of musculoskeletal sarcoma cells

Authors:
- Yuta Kusabe
- Hiroyuki Kawashima
- Akira Ogose
- Taro Sasaki
- Takashi Ariizumi
- Tetsuo Hotta
- Naoto Endo
View Affiliations

Affiliations: School of Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata 851‑8510, Japan, Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata 851‑8510, Japan, Department of Orthopedic Surgery, Niigata Cancer Center Hospital, Niigata 951‑8566, Japan
Published online on: July 17, 2015 https://doi.org/10.3892/ol.2015.3506
Pages: 2511-2518

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Musculoskeletal sarcomas (MSS) are a heterogeneous group of malignancies with relatively high mortality rates. The prognosis for patients with MSS is poor, with few drugs inducing measurable activity. Alkylating agents, namely ifosfamide and dacarbazine, which act nonspecifically on proliferating cells, are the typical therapy prescribed for advanced MSS. A novel alkylating agent, temozolomide (TMZ), has several advantages over existing alkylating agents. TMZ induces the formation of O6‑methylguanine in DNA, thereby inducing mismatches during DNA replication and the subsequent activation of apoptotic pathways. However, due to conflicting data in the literature, the mechanism of TMZ action has remained elusive. Therefore, the present study aimed to evaluate apoptosis in MSS cells treated with TMZ, and to evaluate the correlation between TMZ action and survival pathways, including the phosphoinositide 3‑kinase (PI3K)/Akt and extracellular signal‑regulated kinase (ERK)1/2 mitogen activated protein kinase (MAPK) pathways. Cell proliferation was evaluated by performing an XTT (sodium 3'‑[1‑(phenylaminocarbonyl)‑3,4‑tetrazolium]‑bis (4‑methoxy‑6‑nitro) benzene sulfonic acid hydrate) assay. Apoptotic morphological changes, for example chromatin condensation, were evaluated by fluorescence confocal microscopy. The expression of the apoptosis‑associated proteins caspase‑3, poly adenosine diphosphate ribose polymerase (PARP), Akt and ERK1/2, was determined by western blotting. The results of the present study indicated that, in certain MSS cells, the IC50 value was lower than that in TMZ‑sensitive U‑87 MG cells. Furthermore, TMZ treatment was associated with apoptotic morphological changes and the expression levels of pro‑apoptotic cleaved caspase‑3 and PARP were also increased in TMZ‑treated MSS cells. In addition, the results indicated that PI3K/Akt and ERK1/2 MAPK were constitutively phosphorylated in MSS cells, and phosphorylation of PI3K/Akt was suppressed in certain cells, and maintained in other cells, by TMZ. These observations emphasized the plasticity of MSS cells, and suggested that this plasticity may contribute to the variance in cell sensitivity to TMZ and TMZ-resistance in MSS.

View Figures

View References

1	Gottlieb JA, Benjamin RS, Baker LH, et al: Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 60:199–203. 1976.PubMed/NCBI
2	Stevens MF, Hickman JA, Langdon SP, et al: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47:5846–5852. 1987.PubMed/NCBI
3	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
4	MoreiraGonzalez A, Djohan R and Lohman R: Considerations surrounding reconstruction after resection of musculoskeletal sarcomas. Cleve Clin J Med. 77 (Suppl 1):S18–S22. 2010. View Article : Google Scholar : PubMed/NCBI
5	Trent JC, Beach J, Burgess MA, et al: A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer. 98:2693–2699. 2003. View Article : Google Scholar : PubMed/NCBI
6	Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Bover I and Maurel J: Spanish Group for Research on Sarcomas: A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: A study by the Spanish Group for Research on Sarcomas. Cancer. 104:1706–1712. 2005. View Article : Google Scholar : PubMed/NCBI
7	Stacchiotti S, Tortoreto M, Bozzi F, et al: Dacarbazine in solitary fibrous tumor: A case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. Clin Cancer Res. 19:5192–5201. 2013. View Article : Google Scholar : PubMed/NCBI
8	Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP and Meyers PA: Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 53:1029–1034. 2009. View Article : Google Scholar : PubMed/NCBI
9	Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, Polczyńska K, Rogowska E, RodriguezGalindo C and Wozniak W: Vincristine, irinotecan and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 60:1621–1625. 2013. View Article : Google Scholar : PubMed/NCBI
10	Hotta T, Motoyama T and Watanabe H: Three human osteosarcoma cell lines exhibiting different phenotypic expressions. Acta Pathol Jpn. 42:595–603. 1992.PubMed/NCBI
11	Imaizumi S, Motoyama T, Ogose A, Hotta T and Takahashi HE: Characterization and chemosensitivity of two human malignant peripheral nerve sheath tumour cell lines derived from a patient with neurofibromatosis type 1. Virchows Arch. 433:435–441. 1998. View Article : Google Scholar : PubMed/NCBI
12	Hoshino M, Kawashima H, Ogose A, et al: Serum CA 125 expression as a tumor marker for diagnosis and monitoring the clinical course of epithelioid sarcoma. J Cancer Res Clin Oncol. 136:457–464. 2010. View Article : Google Scholar : PubMed/NCBI
13	Sonobe H, Manabe Y, Furihata M, Iwata J, Oka T, Ohtsuki Y, Mizobuchi H, Yamamoto H, Kumano O and Abe S: Establishment and characterization of a new human synovial sarcoma cell line, HS-SY-II. Lab Invest. 67:498–505. 1992.PubMed/NCBI
14	Kawai A, Naito N, Yoshida A, et al: Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett. 204:105–113. 2004. View Article : Google Scholar : PubMed/NCBI
15	Aman P, Ron D, Mandahl N, et al: Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer. 5:278–285. 1992. View Article : Google Scholar : PubMed/NCBI
16	Hoshino M, Ogose A, Kawashima H, et al: Molecular analyses of cell origin and detection of circulating tumor cells in the peripheral blood in alveolar soft part sarcoma. Cancer Genet Cytogenet. 190:75–80. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kusakabe H, Iwasaki H, Sano K and Kiyokane K: Expression of lung resistance protein in epithelioid sarcoma in vitro and in vivo. Arch Dermatol Res. 292:292–300. 2000. View Article : Google Scholar : PubMed/NCBI
18	FernandesAlnemri T, Litwack G and Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 269:30761–30764. 1994.PubMed/NCBI
19	Oliver FJ, de la Rubia G, Rolli V, et al: Importance of poly (ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem. 273:33533–33539. 1998.PubMed/NCBI
20	Liu H, Zhou L, Shi S, et al: Oligosaccharide G19 inhibits U-87 MG human glioma cells growth in vitro and in vivo by targeting epidermal growth factor (EGF) and activating p53/p21 signaling. Glycobiology. 24:748–765. 2014. View Article : Google Scholar : PubMed/NCBI
21	Wu L, Yang L, Xiong Y, et al: Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells. Tumour Biol. 35:12327–12337. 2014. View Article : Google Scholar : PubMed/NCBI
22	Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
23	Jakob J, Hille M, Sauer C, Ströbel P, Wenz F and Hohenberger P: O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma. Radiat Oncol. 7:1802012. View Article : Google Scholar : PubMed/NCBI
24	DeSalvo M, Maresca G, D'agnano I, et al: Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. Int J Radiat Biol. 87:518–533. 2011. View Article : Google Scholar : PubMed/NCBI
25	Wang H, Cai S, Ernstberger A, Bailey BJ, Wang MZ, Cai W, Goebel WS, Czader MB, Crean C, Suvannasankha A, et al: Temozolomide-mediated DNA methylation in human myeloid precursor cells: Differential involvement of intrinsic and extrinsic apoptotic pathways. Clin Cancer Res. 19:2699–2709. 2013. View Article : Google Scholar : PubMed/NCBI
26	Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo S and Kondo S: Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide. Br J Cancer. 89:922–929. 2003. View Article : Google Scholar : PubMed/NCBI
27	Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF and Kaina B: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O₆-methylguanine. Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
28	Hirose Y, Berger MS and Pieper RO: p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 61:1957–1963. 2001.PubMed/NCBI
29	Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y and Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI
30	Mahalingam D, Mita A, Sankhala K, Swords R, Kelly K, Giles F and Mita MM: Targeting sarcomas: Novel biological agents and future perspectives. Curr Drug Targets. 10:937–949. 2009. View Article : Google Scholar : PubMed/NCBI